Unlock instant, AI-driven research and patent intelligence for your innovation.

Selective hdac8 inhibitors and their uses

Inactive Publication Date: 2018-11-01
HOCHSCHULE DARMSTADT
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes new compounds that are better at inhibiting HDAC8, a protein associated with cancer, than existing compounds. These compounds also have higher activity against cancer cells. Some of these compounds can be made from other compounds, and some of these compounds have higher stability in cells. This information may help researchers develop better methods for treating cancer.

Problems solved by technology

The start of a cancer disease can be caused by environmental influences or the incorporation of toxins into a healthy cell, leading to several damages in its DNA.
Occurring as a natural substrate, acetylated lysines become deacetylated by HDACs resulting in reduced gene expression due to a less accessible DNA structure.
Yet, no substrate could be identified for this protein.
However, most of the very potent HDACi's, in particular TSA, SAHA, Panobinostat, are rather unselective inhibitors.
To avoid these pharmacological issues research for HDAC isoform specific inhibitors became an urgent challenge.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Selective hdac8 inhibitors and their uses
  • Selective hdac8 inhibitors and their uses
  • Selective hdac8 inhibitors and their uses

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0234]1.1 All of the starting materials were obtained commercially and were used without further purification. All of the reported yields are for isolated products and are not optimized. Nuclear magnetic resonance (1H and 13C NMR) spectra were recorded with a Bruker DRX-500 spectrometer (operating at 500 MHz), with chemical shifts in parts per million (8) downfield from TMS, the internal standard. Mass spectral (MS) data were obtained using an Agilent 6110 Quadrupole LC / MS system with a 0.3 mL / min flow rate using a gradient mobile phase consisting of 0.1% trifluoroacetic acid (TFA) in water and 0.1% TFA in acetonitrile. UV detection was monitored at 227 nm. Mass spectra were acquired either in positive or in negative mode scanning over the mass range of 105-1500. The purities of the final compounds were determined using an Agilent 1200 series HPLC system using a C-18 column (Waters Sunfire C18 3.5 μm, 2.1 mm×100 mm) and were found to be >95%. Flash column chroma...

example 2 chemical synthesis

and Structures

[0249]

2.1 General Synthesis of the 2-aryl-4,5-dihydro-1H-imidazole (11, n=2) and 2-aryl-1,4,5,6-tetrahydropyrimidine (11, n=3)

[0250]To a solution of the aldehyde 10 (1 eq.) in tert-butanol (9.0 ml / mmol) the diamine (1.1 eq.) was added and the solution was stirred at 70° C. for 30 min. K2CO3 (4 eq.) and I2 (1.25 eq.) was added at 70° C. and the mixture was stirred at this temperature for further 3 h. The mixture was cooled down to rt and Na2S2O3 was added until the iodine color almost disappear. The organic layer was separated and the solvent was removed in vacuo. The received solid was dissolved in water (7.5 ml / mmol) and 2 N NaOHaq was added until pH=12-14. The aqueous layer was separated with CHCl3 (3×3.75 ml / mmol), the combined organic layers were dried (Na2SO4) and the solvent was removed in vacuo. The product can be used without further purification.

2-(2-Bromophenyl)-1,4,5,6-tetrahydropyrimidine (11a)

[0251]2-Bromobenzaldehyde (10a) (1 ml, 8.56 mmol) and 1,3 diamin...

example 3

Inhibition of Histonedeacetylase Activity

[0298]For HDAC1, 2, 3 and 6:

[0299]The activity of HDAC1 was determined by a colorimetric assay as described by Wegener et al (2003). 1 nM of HDAC1 was incubated with increasing concentrations of the respective compound for 30 minutes at 30° C. The reaction was initiated by addition of 50 μM of the substrate Boc-Lys(Ac)-AMC. After an incubation of 60 minutes the reaction was stopped by addition of 20 μM SAHA and the deacetylated substrate was converted into a fluorescent product by the addition of trypsin.

[0300]For HDAC4, 5, 7 and 8:

[0301]The activity of HDAC4 was determined by a colorimetric assay as described by Wegener et al. (2003). 1 nM of HDAC4 was incubated with increasing concentrations of the respective compound for 30 minutes at 30° C. The reaction was initiated by addition of 20 μM of the substrate Boc-Lys(trifluoracetyl)-AMC. After an incubation of 60 minutes the reaction was stopped by addition of 20 μM SAHA and the deacetylated s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to small molecule compounds based on benzopyrimido- or benzoimidazo-thiazin-imine as well as their (synthesis) intermediates and their use as HDAC inhibitors, in particular HDAC8 inhibitors. The present invention also relates to the use of said compounds in the treatment of cancer and as therapeutic agents for eukaryotic parasites and respective methods of treatment.

Description

[0001]The present invention relates to small molecule compounds based on benzopyrimido- or benzoimidazo-thiazin-imine as well as their (synthesis) intermediates and their use as HDAC inhibitors, in particular HDAC8 inhibitors. The present invention also relates to the use of said compounds in the treatment of cancer and as therapeutic agents for eukaryotic parasites and respective methods of treatment.BACKGROUND OF THE INVENTION[0002]Today, cancer is still one of the most threatening diseases in common societies. 13% of the worldwide deaths (7.9 million people) in 2007 were caused by cancer. As the second most common cause of death (USA), exceeded only by heart diseases, cancer remains a burden to the health and even the funds off many societies (see e.g. Cancer Facts & Figures 2009). The start of a cancer disease can be caused by environmental influences or the incorporation of toxins into a healthy cell, leading to several damages in its DNA. Cancer cells are characterized by thei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/542A61P35/00A61K45/06
CPCA61K31/542A61P35/00A61K45/06C07D513/04Y02A50/30
Inventor MEYER-ALMES, FRANZ-JOSEFMEYNERS, CHRISTIANKLEINSCHEK, ALEXANDERHAUS, PATRICIA
Owner HOCHSCHULE DARMSTADT